[{"orgOrder":0,"company":"Oncology Pharma","sponsor":"NanoSmart Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Dactinomycin","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Oncology Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oncology Pharma \/ Oncology Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Oncology Pharma \/ Oncology Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Oncology Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The licensed technology possesses proprietary technology and intellectual property rights for the development of pharmaceutical drug formulations that are liposomal and/or emulsion-based formulations and that may incorporate Anti-Nuclear Antibodies (ANA)...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 31, 2021

                          Lead Product(s) : Dactinomycin

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : NanoSmart Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank